Short answer
DiaMedica Therapeutics Inc. (DMAC) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
DiaMedica Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full financial results and management commentary available in Exhibit 99.1
- Results announcement provides investors an updated view of liquidity, operating performance and development spending
Item EX-99.1 · Exhibit EX-99.1
- FGR enrollment complete for first two cohorts, 12 participants at 5 and 10 µg/kg, with preliminary topline results scheduled November 24
- ReMEDy2 stroke trial exceeded 200 participants, enabling DSMB interim analysis after 90-day follow-up, expected Q1 2027
- Cash, equivalents and short-term investments $34.9M, supporting planned operations into Q4 2027 under current plans
- Nine-month operating cash use increased to $26.0M from $21.3M, while net loss widened to $31.5M from $24.0M
- R&D expense rose to $25.4M for nine months from $17.9M, reflecting expanded clinical activity and global trial development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other DiaMedica Therapeutics Inc. 8-K filings
Get the next DMAC 8-K as it lands
Follow DMAC for push alerts, or ask the research agent what this filing means.